[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - 2021 - europepmc.org
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
S Jangra, C Ye, R Rathnasinghe… - … : the preprint server …, 2021 - pubmed.ncbi.nlm.nih.gov
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - (No Title), 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> One year in the coronavirus disease 2019
(COVID-19) pandemic, the first vaccines are being rolled out under emergency use …
(COVID-19) pandemic, the first vaccines are being rolled out under emergency use …
[PDF][PDF] NY, USA 13
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - scienceopen.com
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being 19 rolled out under emergency use authorizations. It is of great concern that newly …
being 19 rolled out under emergency use authorizations. It is of great concern that newly …
[PDF][PDF] NY, USA 13
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - researchgate.net
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being 19 rolled out under emergency use authorizations. It is of great concern that newly …
being 19 rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - medRxiv, 2021 - medrxiv.org
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - 2021 - pesquisa.bvsalud.org
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
S Jangra, C Ye, R Rathnasinghe… - Medrxiv: the Preprint …, 2021 - europepmc.org
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
S Jangra, C Ye, R Rathnasinghe, D Stadlbauer… - 2021 - pesquisa.bvsalud.org
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish
neutralizing activity of human convalescent and post-vaccination sera. | PREPRINT-MEDRXIV …
neutralizing activity of human convalescent and post-vaccination sera. | PREPRINT-MEDRXIV …